Progenics Pharmaceuticals (Progenics Pharmaceuticals) Operating Income : $-64.09 Mil (TTM As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Operating Income?

Progenics Pharmaceuticals's Operating Income for the three months ended in Mar. 2020 was $-16.19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2020 was $-64.09 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Progenics Pharmaceuticals's Operating Income for the three months ended in Mar. 2020 was $-16.19 Mil. Progenics Pharmaceuticals's Revenue for the three months ended in Mar. 2020 was $6.25 Mil. Therefore, Progenics Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 was -259.06%.

Progenics Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Progenics Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2020 was -100.29%. Progenics Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2020 was -214.16%.

Progenics Pharmaceuticals Operating Income Historical Data

The historical data trend for Progenics Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Operating Income Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Operating Income

Get a 7-Day Free Trial

-37.70

8.50

-55.80

-48.96

-65.24

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Operating Income	Get a 7-Day Free Trial															-17.34	-18.18	-18.62	-11.12	-16.19

Progenics Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.09 Mil.

Progenics Pharmaceuticals (NAS:PGNX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Progenics Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2020 is calculated as:

	ROC % (Q: Mar. 2020 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2019 )	+	Invested Capital (Q: Mar. 2020 ))	/ count )
=	-64.744 * ( 1 - 0% )	/	( (63.454	+	65.654)	/ 2 )
=	-64.744	/	64.554
=	-100.29 %

where

	Invested Capital		(Q: Dec. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	119.47	-	14.352	-	( 42.049	-	max(0, 22.068	-	63.732	+	42.049	))
=	63.454

	Invested Capital		(Q: Mar. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	98.344	-	11.243	-	( 29.531	-	max(0, 19.099	-	40.546	+	29.531	))
=	65.654

Note: The Operating Income data used here is four times the quarterly (Mar. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Progenics Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2020 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2020 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2019		Q: Mar. 2020
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-64.744	/	( ( (25.181 + max(7.331, 0))	+	(27.952 + max(-0.228, 0)) )	/	2 )
=	-64.744	/	( ( 32.512	+	27.952 )	/	2 )
=	-64.744	/	30.232
=	-214.16 %

where Working Capital is:

	Working Capital		(Q: Dec. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(15.976	+	0	+	5.707)	-	(14.352	+	0	+	0)
=	7.331

	Working Capital		(Q: Mar. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.19	+	0	+	4.825)	-	(11.243	+	0	+	0)
=	-0.228

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2020) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Progenics Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2020 )	/	Revenue (Q: Mar. 2020 )
	=	-16.186	/	6.248
	=	-259.06 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Progenics Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Executives

Asha Das	officer: Chief Medical Officer	C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli	director	SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman	10 percent owner, other: See Explanation of Responses	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria	10 percent owner, other: See Explanation of Responses	1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams	director
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022